Related Experiment Videos
Apraclonidine. A one-week dose-response study
H D Jampel1, A L Robin, H A Quigley
1Glaucoma Services, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|August 1, 1988
Summary
Apraclonidine hydrochloride effectively lowers elevated intraocular pressure (IOP) in a dose-dependent manner. Higher concentrations (0.25% and 0.5%) showed maximal IOP reduction, with minimal systemic effects observed.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Elevated intraocular pressure (IOP) is a significant risk factor for glaucoma.
- Pharmacological interventions are crucial for managing IOP and preventing vision loss.
Purpose of the Study:
- To evaluate the dose-response relationship of apraclonidine hydrochloride in reducing elevated IOP.
- To assess the efficacy and safety of different apraclonidine concentrations.
Main Methods:
- A double-masked, cross-over, dose-response study was conducted.
- Twenty patients with elevated IOP received three concentrations of apraclonidine (0.125%, 0.25%, 0.5%) and vehicle control.
- IOP, pupillary diameter, interpalpebral fissure width, blood pressure, and pulse were monitored over time.
Main Results:
- All apraclonidine concentrations significantly reduced IOP compared to vehicle.
- 0.5% and 0.25% apraclonidine demonstrated maximal IOP reduction (average 27% decrease, 8.7 mm Hg).
- Higher concentrations were more effective than 0.125% at 2 and 8 hours; interpalpebral fissure width increased dose-dependently.
Conclusions:
- Apraclonidine hydrochloride is an effective agent for lowering elevated IOP.
- The 0.25% and 0.5% concentrations provide significant IOP reduction with minimal systemic side effects.
- Transient dry nose or mouth were reported, potentially dose-dependent.